Serum uric acid as an independent and incremental prognostic marker in addition to N-Terminal Pro-B-Type natriuretic peptide in patients with acute myocardial infarction

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1440-1447

  Bae, Myung Hwan ^a   Lee, Jang Hoon ^a   Lee, Sang Hyuk ^a   Park, Sun Hee ^a   Yang, Dong Heon ^a   Park, Hun Sik ^a   Cho, Yongkeun ^a   Jun, Jae Eun ^a   Chae, Shung Chull ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Myocardial infarction; Prognosis; Uric acid

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; URIC ACID;

ACUTE HEART INFARCTION; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HEART RATE; HUMAN; KOREA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION; URIC ACID;

EID: 79957710234     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0952     Document Type: Article

References (34)

1. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: Insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003; 107: 1951-1953.
2. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104: 2407-2411.
3. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-1997.
4. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858-865.
5. Fessel WJ. High uric acid as an indicator of cardiovascular disease: Independence from obesity. Am J Med 1980; 68: 401-404.
6. Hongo M, Hidaka H, Sakaguchi S, Nakanishi K, Ichikawa M, Hirota N, et al; on behalf of the Investigators of Study Project on Prevention of Metabolic Syndrome among Children, Adolescents, and Young Adults in Shinshu. Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students. Circ J 2010; 74: 1570-1577.
7. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease: The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-644.
8. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
9. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992: National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410.
10. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-1956.
11. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: A marker of chronic inflammation. Eur Heart J 1998; 19: 1814-1822.
12. Homayounfar S, Ansari M, Kashani KM. Evaluation of independent prognostic importance of hyperuricemia in hospital death after acute myocardial infarction. Saudi Med J 2007; 28: 759-761.
13. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M, et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (The Japanese Acute Coronary Syndrome Study). Am J Cardiol 2005; 96: 489-495.
14. Lazzeri C, Valente S, Chiostri M, Sori A, Bernardo P, Gensini GF. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: Its prognostic role and relation with inflammatory markers: A single center experience. Int J Cardiol 2010; 138: 206-209.
15. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40: 437-445.
16. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-2918.
17. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275-281.
18. Kwon TG, Bae JH, Jeong MH, Kim YJ, Hur SH, Seong IW, et al. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention. Int J Cardiol 2009; 133: 173-178.
19. Lee JH, Park HS, Chae SC, Cho Y, Yang DH, Jeong MH, et al. Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea Acute Myocardial Infarction Registry). Am J Cardiol 2009; 104: 182-189.
20. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513.
21. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: Prevalence, clinical characteristics, and prognostic importance. Am J Cardiol 2006; 97: 13F-25F.
22. Yildiz A, Yilmaz R, Demirbag R, Gur M, Bas MM, Erel O. Association of serum uric acid level and coronary blood flow. Coron Artery Dis 2007; 18: 607-613.
23. Cin VG, Pekdemir H, Camsar A, Ciçek D, Akkus MN, Parmaksýz T, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 2003; 44: 907-919.
24. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.
25. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
26. Ruggiero C, Cherubini A, Miller E 3rd, Maggio M, Najjar SS, Lauretani F, et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol 2007; 100: 115-121.
27. Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF 2nd, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007; 20: 83-89.
28. Benderly M, Haim M, Boyko V, Tanne D, Behar S, Matas Z, et al. C-reactive protein distribution and correlates among men and women with chronic coronary heart disease. Cardiology 2007; 107: 345-353.
29. Brodov Y, Behar S, Goldenberg I, Boyko V, Chouraqui P. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study). Am J Cardiol 2009; 104: 194-198.
30. Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J 2006; 70: 379-1384.
31. Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Schweda S, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length. Circulation 2000; 102: 3074-3079.
32. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of Btype natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
33. Sugimoto M, Manabe H, Nakau K, Furuya A, Okushima K, Fujiyasu H, et al. The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children: Correlation with the heart failure score and comparison with B-type natriuretic peptide. Circ J 2010; 74: 998-1005.
34. Sakai H, Tsutamoto T, Tsutsui T, Tanaka T, Ishikawa C, Horie M. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ J 2006; 70: 1006-1011.